GPhA In Talks With Trump On Drug Pricing, Lukewarm On Priority Review Voucher Bill

The Generic Pharmaceutical Association (GPhA) is in talks with both the Trump administration and members of Congress on ways to increase generic competition, Chip Davis, GPhA president and CEO, told Inside Health Policy Feb. 2 in an exclusive interview. The group sent a letter to the Trump team in December, urging him to pursue policies that include repealing the Medicaid rebate increase for generics, clearing FDA's generic backlog and withdrawing FDA's controversial rule requiring generic drug companies to update...